Evidence map›Paper›PMID 39866362›Full record

ArticleLancet regional health. Americas2025

SARS-COV-2 re-infection and incidence of post-acute sequelae of COVID-19 (PASC) among essential workers in New York: a retrospective cohort study.

Tesleem K Babalola, Sean A P Clouston, Zennur Sekendiz, Devi Chowdhury, Nicola Soriolo, Joseph Kawuki, Jaymie Meliker, Melissa Carr, Bruno R Valenti, Ashley Fontana and 3 more

Abstract read
In one paragraph

Article in Lancet regional health. Americas, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Observational
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Tesleem K BabalolaProgram in Public Health, Renaissance School of Medicine, Stony Brook University, NY, USA.
Sean A P CloustonProgram in Public Health, Renaissance School of Medicine, Stony Brook University, NY, USA.
Zennur SekendizWorld Trade Center Health Program, Renaissance School of Medicine, Stony Brook University, NY, USA.
Devi ChowdhuryWorld Trade Center Health Program, Renaissance School of Medicine, Stony Brook University, NY, USA.
Nicola SorioloPreventive Medicine Division, Department of Family, Population and Preventive Medicine, Stony Brook University, NY, USA.
Joseph KawukiProgram in Public Health, Renaissance School of Medicine, Stony Brook University, NY, USA.
Jaymie MelikerProgram in Public Health, Renaissance School of Medicine, Stony Brook University, NY, USA.
Melissa CarrWorld Trade Center Health Program, Renaissance School of Medicine, Stony Brook University, NY, USA.
Bruno R ValentiWorld Trade Center Health Program, Renaissance School of Medicine, Stony Brook University, NY, USA.
Ashley FontanaWorld Trade Center Health Program, Renaissance School of Medicine, Stony Brook University, NY, USA.
Onix A MelendezWorld Trade Center Health Program, Renaissance School of Medicine, Stony Brook University, NY, USA.
Olga MorozovaDepartment of Public Health Sciences, University of Chicago, Chicago, IL, USA.
Benjamin J LuftWorld Trade Center Health Program, Renaissance School of Medicine, Stony Brook University, NY, USA.

Funding

A lifecourse approach to PTSD and cognitive aging: A cohort of 9/11 respondersR01AG049953 · NIA · STATE UNIVERSITY NEW YORK STONY BROOK · PI CLOUSTON, SEAN · 2015 to 2024
$11.0M
NIA NIH HHS R01 AG049953NIOSH CDC HHS U01 OH011864NIOSH CDC HHS U01 OH012275
6 · The paper itself

Abstract

Background: After surviving Coronavirus Disease 2019 (COVID-19), some people develop symptoms known as post-acute sequelae of COVID-19 (PASC). PASC is an emerging phenomenon yet to be fully understood, and identifying risk factors has been challenging. This study investigated the association between the number of COVID-19 episodes and the incidence of PASC among essential workers. Methods: We analyzed data from 2511 essential workers, mainly first responders, with confirmed polymerase chain reaction, antibody, or antigen-positive test results for SARS-CoV-2 infection from March 2020 to February 2024. Data were collected through in-person questionnaires and surveys sent via text and email, internal medical records, follow-up calls, and external medical records. Participants who reported continuation or the development of new symptoms three months after the initial SARS-CoV-2 infection, with symptoms lasting for at least two months, were categorized as having PASC, while those without any COVID-19 or whose symptoms resolved were classified as non-PASC. PASC was common in this cohort so we used a Poisson regression model to compute multivariable-adjusted Relative Risk (RR) for the association between risk of PASC and SARS-CoV-2 re-infection, severity, and vaccination status at first infection. Findings: A total of 475 (prevalence = 18.9%, [95% confidence interval] = [17.4-20.5]) PASC patients were identified. The mean (standard deviation (SD)) age of participants who experienced PASC (54.8 (7.2) years) was similar to those who did not (54.2 (7.4) years). There were 403 (16.1% [14.6-17.5]) participants who experienced multiple instances of COVID-19. After adjusting for relevant demographic, lifestyle, and clinical variables, we found a significant association between the risk of experiencing PASC and multiple SARS-COV-2 infections (RR = 1.41 [1.14-1.74]), severe COVID-19 (RR = 3.17 [2.41-4.16]), and being unvaccinated at first infection (RR = 3.29 [2.46-4.41]). Interpretation: Although the pathogenetic mechanism for PASC remains unclear, identifying risk factors such as lack of vaccination or re-infection can assist in better understanding and managing the condition. Funding: National Institute on Aging (NIH/NIA R01 AG049953) and Centers for Disease Control and Prevention (CDC/NIOSH U01 OH011864) and (CDC/NIOSH U01 OH012275).

Indexed as

COVID-19Post-COVID-19ReinfectionSARS-COV-2SeverityVaccination

Identifiers

PMID39866362
PMCPMC11764319

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.